CLINICAL TRIALS PROFILE FOR ZIPRASIDONE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Ziprasidone Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00014001 ↗ | CATIE- Schizophrenia Trial | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2000-12-01 | The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate. |
| NCT00034801 ↗ | Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia | Completed | Eli Lilly and Company | Phase 4 | 2001-09-01 | This is a research study comparing the safety and efficacy of two active study medications |
| NCT00044655 ↗ | Switching Medication to Treat Schizophrenia | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2001-07-01 | This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. |
| NCT00044655 ↗ | Switching Medication to Treat Schizophrenia | Completed | Icahn School of Medicine at Mount Sinai | Phase 4 | 2001-07-01 | This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. |
| NCT00048802 ↗ | Treatment and Outcome of Early Onset Bipolar Disorder | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2002-08-01 | This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder. |
| NCT00048802 ↗ | Treatment and Outcome of Early Onset Bipolar Disorder | Completed | Northwell Health | Phase 4 | 2002-08-01 | This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder. |
| NCT00096863 ↗ | The MIND Study: Modifying the INcidence of Delirium | Completed | Vanderbilt University | Phase 2 | 2004-12-01 | Delirium is associated with increased risk of death, prolonged stay, higher cost of care, and likely long-term brain deficits in survivors. This form of brain dysfunction occurs in intensive care unit (ICU) patients in epidemic proportions, and the scope of this problem is likely to worsen in upcoming years due to the aging of our population and increased utilization of the ICU. Currently, delirium goes unrecognized and untreated in the vast majority of circumstances in the ICU unless the patient presents with hyperactive delirium and agitation. In the latter circumstance, a commonly used typical antipsychotic called haloperidol is considered the principal agent for treating delirium based largely on anecdotal evidence to support its usefulness, though no placebo controlled trials exist. There are no FDA approved medications for delirium. The atypical antipsychotics provide a promising alternative for the treatment of delirium due to their enhanced beneficial effects on positive (agitated) and negative (quiet) symptoms proven in mania and schizophrenia, reduced risk for side effects common to haloperidol such as extrapyramidal symptomatology, and less potentially lethal heart rhythm disturbances. It is imperative that well-designed phase II studies to determine proof of principle be conducted. A pilot study of feasibility to begin assessing the role of antipsychotics in the management of ICU delirium. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Ziprasidone Hydrochloride
Condition Name
Clinical Trial Locations for Ziprasidone Hydrochloride
Trials by Country
Clinical Trial Progress for Ziprasidone Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Ziprasidone Hydrochloride
Sponsor Name
